No potential conflicts of interest were disclosed. Financial support was provided as follows: BMBF: NGFNPlus (#01GS0896, F. Westermann) , European Union (EU, FP6): E.E.T. Pipeline (#037260, S. Gogolin, F. Westermann), EU (FP7): ASSET (S.
Gogolin, F. Westermann), BMBF: NGFNPlus ENGINE (N. Harder, R. Batra, N. Diessl, R. König), FANCI SysTec (N. Harder), Helmholtz Alliance on Systems Biology (SB Cancer, D.141100/07.997, N. Harder, R. Batra, N. Diessl, R. König).
high MYCN
81 Manuskript II
3.8 References
[1] B.A. Weaver, D.W. Cleveland, Does aneuploidy cause cancer?, Current opinion in cell biology 18 (2006) 658‐667
[2] R. Spitz, B. Hero, T. Simon, F. Berthold, Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma, Clin Cancer Res 12 (2006) 3368‐3373
[3] E.F. Attiyeh, W.B. London, Y.P. Mosse, Q. Wang, C. Winter, D. Khazi, P.W. McGrady, R.C.
Seeger, A.T. Look, H. Shimada, G.M. Brodeur, S.L. Cohn, K.K. Matthay, J.M. Maris, Chromosome 1p and 11q deletions and outcome in neuroblastoma, The New England
[5] R.C. Seeger, G.M. Brodeur, H. Sather, A. Dalton, S.E. Siegel, K.Y. Wong, D. Hammond, Association of multiple copies of the N‐myc oncogene with rapid progression of neuroblastomas, The New England journal of medicine 313 (1985) 1111‐1116
[6] R. Ladenstein, I.M. Ambros, U. Potschger, G. Amann, C. Urban, F.M. Fink, K. Schmitt, R.
Jones, M. Slociak, F. Schilling, J. Ritter, F. Berthold, H. Gadner, P.F. Ambros, Prognostic significance of DNA di‐tetraploidy in neuroblastoma, Medical and pediatric oncology 36 (2001) 83‐92
[7] R. Bagatell, P. Rumcheva, W.B. London, S.L. Cohn, A.T. Look, G.M. Brodeur, C. Frantz, V.
Joshi, P. Thorner, P.V. Rao, R. Castleberry, L.C. Bowman, Outcomes of children with intermediate‐risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy, J Clin Oncol 23 (2005) 8819‐8827
[8] R.E. George, W.B. London, S.L. Cohn, J.M. Maris, C. Kretschmar, L. Diller, G.M. Brodeur, R.P. Castleberry, A.T. Look, Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study, J Clin Oncol 23 (2005) 6466‐6473
[9] J. Schneiderman, W.B. London, G.M. Brodeur, R.P. Castleberry, A.T. Look, S.L. Cohn, Clinical significance of MYCN amplification and ploidy in favorable‐stage neuroblastoma: a report from the Children's Oncology Group, J Clin Oncol 26 (2008)
[11] F. Westermann, M. Schwab, Genetic parameters of neuroblastomas, Cancer letters 184 (2002) 127‐147
[12] N.J. Ganem, Z. Storchova, D. Pellman, Tetraploidy, aneuploidy and cancer, Current opinion in genetics & development 17 (2007) 157‐162
[13] Z. Storchova, D. Pellman, From polyploidy to aneuploidy, genome instability and cancer, Nature reviews 5 (2004) 45‐54
[14] T. Fujiwara, M. Bandi, M. Nitta, E.V. Ivanova, R.T. Bronson, D. Pellman, Cytokinesis failure generating tetraploids promotes tumorigenesis in p53‐null cells, Nature 437 (2005) 1043‐1047
[15] M.T. Barrett, D. Pritchard, C. Palanca‐Wessels, J. Anderson, B.J. Reid, P.S. Rabinovitch, Molecular phenotype of spontaneously arising 4N (G2‐tetraploid) intermediates of neoplastic progression in Barrett's esophagus, Cancer research 63 (2003) 4211‐4217
[16] A.J. Olaharski, R. Sotelo, G. Solorza‐Luna, M.E. Gonsebatt, P. Guzman, A. Mohar, D.A.
Eastmond, Tetraploidy and chromosomal instability are early events during cervical carcinogenesis, Carcinogenesis 27 (2006) 337‐343
[17] Z. Storchova, C. Kuffer, The consequences of tetraploidy and aneuploidy, Journal of cell science 121 (2008) 3859‐3866
[18] R. Sotillo, E. Hernando, E. Diaz‐Rodriguez, J. Teruya‐Feldstein, C. Cordon‐Cardo, S.W.
Lowe, R. Benezra, Mad2 overexpression promotes aneuploidy and tumorigenesis in mice, Cancer cell 11 (2007) 9‐23
[19] C.L. Rieder, H. Maiato, Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint, Developmental cell 7 (2004) 637‐651 V. Mittal, W. Gerald, R. Benezra, S.W. Lowe, C. Cordon‐Cardo, Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control, Nature 430 (2004) 797‐802
[23] M. Malumbres, Oncogene‐induced mitotic stress: p53 and pRb get mad too, Cancer cell 19 (2011) 691‐692
83 Manuskript II
[24] J. Carr‐Wilkinson, K. O'Toole, K.M. Wood, C.C. Challen, A.G. Baker, J.R. Board, L. Evans, M. Cole, N.K. Cheung, J. Boos, G. Kohler, I. Leuschner, A.D. Pearson, J. Lunec, D.A.
Tweddle, High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma, Clin Cancer Res 16 (2010) 1108‐1118
[25] J.J. Molenaar, M.E. Ebus, J. Koster, P. van Sluis, C.J. van Noesel, R. Versteeg, H.N. Caron, Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma, Cancer research 68 (2008) 2599‐2609
[26] J.J. Molenaar, P. van Sluis, K. Boon, R. Versteeg, H.N. Caron, Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma, Genes, chromosomes &
[28] F. Westermann, D. Muth, A. Benner, T. Bauer, K.O. Henrich, A. Oberthuer, B. Brors, T.
Beissbarth, J. Vandesompele, F. Pattyn, B. Hero, R. Konig, M. Fischer, M. Schwab, Distinct transcriptional MYCN/c‐MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas, Genome biology 9 (2008) R150
[29] I. Eckerle, D. Muth, J. Batzler, K.O. Henrich, W. Lutz, M. Fischer, O. Witt, M. Schwab, F.
Westermann, Regulation of BIRC5 and its isoform BIRC5‐2B in neuroblastoma, Cancer letters 285 (2009) 99‐107
[30] J. Seoane, H.V. Le, J. Massague, Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage, Nature 419 (2002) 729‐
734
[31] P.C. Galipeau, D.S. Cowan, C.A. Sanchez, M.T. Barrett, M.J. Emond, D.S. Levine, P.S.
Rabinovitch, B.J. Reid, 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus, Proceedings of the National Academy of Sciences of the United States of America 93 (1996) 7081‐7084
[32] D.T. Jones, N. Jager, M. Kool, T. Zichner, B. Hutter, M. Sultan, Y.J. Cho, T.J. Pugh, V.
Hovestadt, A.M. Stutz, T. Rausch, H.J. Warnatz, M. Ryzhova, S. Bender, D. Sturm, S.
Pleier, H. Cin, E. Pfaff, L. Sieber, A. Wittmann, M. Remke, H. Witt, S. Hutter, T.
Tzaridis, J. Weischenfeldt, B. Raeder, M. Avci, V. Amstislavskiy, M. Zapatka, U.D.
Weber, Q. Wang, B. Lasitschka, C.C. Bartholomae, M. Schmidt, C. von Kalle, V. Ast, C.
Lawerenz, J. Eils, R. Kabbe, V. Benes, P. van Sluis, J. Koster, R. Volckmann, D. Shih, M.J. Betts, R.B. Russell, S. Coco, G.P. Tonini, U. Schuller, V. Hans, N. Graf, Y.J. Kim, C.
Monoranu, W. Roggendorf, A. Unterberg, C. Herold‐Mende, T. Milde, A.E. Kulozik, A.
von Deimling, O. Witt, E. Maass, J. Rossler, M. Ebinger, M.U. Schuhmann, M.C.
Fruhwald, M. Hasselblatt, N. Jabado, S. Rutkowski, A.O. von Bueren, D. Williamson, S.C. Clifford, M.G. McCabe, V.P. Collins, S. Wolf, S. Wiemann, H. Lehrach, B. Brors, W.
Scheurlen, J. Felsberg, G. Reifenberger, P.A. Northcott, M.D. Taylor, M. Meyerson, S.L. Pomeroy, M.L. Yaspo, J.O. Korbel, A. Korshunov, R. Eils, S.M. Pfister, P. Lichter, Dissecting the genomic complexity underlying medulloblastoma, Nature 488 (2012) 100‐105
[33] L. Schweigerer, S. Breit, A. Wenzel, K. Tsunamoto, R. Ludwig, M. Schwab, Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells:
evidence for induction of autocrine growth factor activity, Cancer research 50 (1990) 4411‐4416
[34] L. Schweigerer, P. Scheurich, T. Fotsis, Enhanced MYCN oncogene expression in human neuroblastoma cells results in increased susceptibility to growth inhibition by TNF alpha, Biochemical and biophysical research communications 170 (1990) 1301‐1307 of N‐myc in human neuroblastoma cells increases expression of alpha‐prothymosin and ornithine decarboxylase and accelerates progression into S‐phase early after mitogenic stimulation of quiescent cells, Oncogene 13 (1996) 803‐812
[37] V. Ehemann, B. Hashemi, A. Lange, H.F. Otto, Flow cytometric DNA analysis and chromosomal aberrations in malignant glioblastomas, Cancer letters 138 (1999) 101‐ Reverse transfection on cell arrays for high content screening microscopy, Nature protocols 2 (2007) 392‐399
[40] N. Harder, R. Batra, S. Gogolin, N. Diessl, R. Eils, F. Westermann, R. König, K. Rohr, Large‐
Scale Tracking for Cell Migration and Proliferation Analysis and Experimental Optimization of High‐Throughput Screens, Proc. 6th Internat. Workshop on Microscopic Image Analysis with Applications in Biology (MIAAB '11) (2011)
85
Holstege, T.R. Brummelkamp, R. Agami, H. Clevers, Specific inhibition of gene expression using a stably integrated, inducible small‐interfering‐RNA vector, EMBO reports 4 (2003) 609‐615
[43] E.A. Afanasyeva, P. Mestdagh, C. Kumps, J. Vandesompele, V. Ehemann, J. Theissen, M.
Fischer, M. Zapatka, B. Brors, L. Savelyeva, V. Sagulenko, F. Speleman, M. Schwab, F.
Westermann, MicroRNA miR‐885‐5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival, Cell death and differentiation 18 (2011) 974‐984
[44] O. Henegariu, P. Bray‐Ward, D.C. Ward, Custom fluorescent‐nucleotide synthesis as an alternative method for nucleic acid labeling, Nature biotechnology 18 (2000) 345‐348
[45] L. Savelyeva, E. Sagulenko, J.G. Schmitt, M. Schwab, The neurobeachin gene spans the common fragile site FRA13A, Human genetics 118 (2006) 551‐558
[46] P. Kett, B. Geiger, V. Ehemann, D. Komitowski, Three‐dimensional analysis of cell nucleus structures visualized by confocal scanning laser microscopy, J Microsc 167 (1992) 169‐179
[47] A. Oberthuer, F. Berthold, P. Warnat, B. Hero, Y. Kahlert, R. Spitz, K. Ernestus, R. Konig, S. Haas, R. Eils, M. Schwab, B. Brors, F. Westermann, M. Fischer, Customized oligonucleotide microarray gene expression‐based classification of neuroblastoma patients outperforms current clinical risk stratification, J Clin Oncol 24 (2006) 5070‐
5078
[48] W. Huang da, B.T. Sherman, R.A. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, Nature protocols 4 (2009) 44‐57
[49] K.O. Henrich, M. Fischer, D. Mertens, A. Benner, R. Wiedemeyer, B. Brors, A. Oberthuer, F. Berthold, J.S. Wei, J. Khan, M. Schwab, F. Westermann, Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients, Clin Cancer Res 12 (2006) 131‐138
[50] T. Hothorn, K. Hornik, A. Zeileis, Unbiased Recursive Partitioning: A Conditional Inference Framework, Journal of Computational and Graphical Statistics 15 (2006) 651‐674
[51] D.J. Gordon, B. Resio, D. Pellman, Causes and consequences of aneuploidy in cancer, Nature reviews. Genetics 13 (2012) 189‐203
[52] F. Westermann, K.O. Henrich, J.S. Wei, W. Lutz, M. Fischer, R. Konig, R. Wiedemeyer, V.
Ehemann, B. Brors, K. Ernestus, I. Leuschner, A. Benner, J. Khan, M. Schwab, High Skp2 expression characterizes high‐risk neuroblastomas independent of MYCN status, Clin Cancer Res 13 (2007) 4695‐4703
[53] J.S. Lanni, T. Jacks, Characterization of the p53‐dependent postmitotic checkpoint following spindle disruption, Molecular and cellular biology 18 (1998) 1055‐1064
[54] Z.A. Stewart, D. Mays, J.A. Pietenpol, Defective G1‐S cell cycle checkpoint function sensitizes cells to microtubule inhibitor‐induced apoptosis, Cancer research 59 (1999) 3831‐3837
[55] D.A. Tweddle, A.J. Malcolm, N. Bown, A.D. Pearson, J. Lunec, Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line, Cancer research 61 (2001) 8‐13
[57] M.V. Blagosklonny, Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events, Cell cycle (Georgetown, Tex 6 (2007) 70‐74
[58] W.M. Zhao, G. Fang, Anillin is a substrate of anaphase‐promoting complex/cyclosome (APC/C) that controls spatial contractility of myosin during late cytokinesis, The Journal of biological chemistry 280 (2005) 33516‐33524
[59] J.V. Shah, D.W. Cleveland, Waiting for anaphase: Mad2 and the spindle assembly checkpoint, Cell 103 (2000) 997‐1000
[60] S. Martin‐Lluesma, V.M. Stucke, E.A. Nigg, Role of Hec1 in spindle checkpoint signaling and kinetochore recruitment of Mad1/Mad2, Science 297 (2002) 2267‐2270
[61] J. Thacker, The RAD51 gene family, genetic instability and cancer, Cancer letters 219 (2005) 125‐135
[62] P. Giannakakou, D.L. Sackett, Y. Ward, K.R. Webster, M.V. Blagosklonny, T. Fojo, p53 is associated with cellular microtubules and is transported to the nucleus by dynein, Nature cell biology 2 (2000) 709‐717
[63] W.F. Ooi, A. Re, V. Sidarovich, V. Canella, N. Arseni, V. Adami, G. Guarguaglini, M.
Giubettini, P. Scaruffi, S. Stigliani, P. Lavia, G.P. Tonini, A. Quattrone, Segmental
87 Manuskript II
chromosome aberrations converge on overexpression of mitotic spindle regulatory genes in high‐risk neuroblastoma, Genes, chromosomes & cancer (2012)
[64] A.L. Krasnoselsky, C.C. Whiteford, J.S. Wei, S. Bilke, F. Westermann, Q.R. Chen, J. Khan, Altered expression of cell cycle genes distinguishes aggressive neuroblastoma, Oncogene 24 (2005) 1533‐1541
[65] A. Menssen, A. Epanchintsev, D. Lodygin, N. Rezaei, P. Jung, B. Verdoodt, J. Diebold, H.
Hermeking, c‐MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c‐MYC‐induced DNA damage and chromosomal instability, Cell cycle (Georgetown, Tex 6 (2007) 339‐352
[66] G. Fang, H. Yu, M.W. Kirschner, The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase‐promoting complex to control anaphase initiation, Genes & development 12 (1998) 1871‐1883
[67] S.L. Thompson, D.A. Compton, Proliferation of aneuploid human cells is limited by a p53‐dependent mechanism, The Journal of cell biology 188 (2010) 369‐381
[68] J.A. Barboza, G. Liu, Z. Ju, A.K. El‐Naggar, G. Lozano, p21 delays tumor onset by preservation of chromosomal stability, Proceedings of the National Academy of Sciences of the United States of America 103 (2006) 19842‐19847
[69] D.A. Tweddle, A.D. Pearson, M. Haber, M.D. Norris, C. Xue, C. Flemming, J. Lunec, The p53 pathway and its inactivation in neuroblastoma, Cancer letters 197 (2003) 93‐98
[70] G.M. Brodeur, A.A. Green, F.A. Hayes, K.J. Williams, D.L. Williams, A.A. Tsiatis, Cytogenetic features of human neuroblastomas and cell lines, Cancer research 41 (1981) 4678‐4686
[71] R.C. Seeger, S.A. Rayner, A. Banerjee, H. Chung, W.E. Laug, H.B. Neustein, W.F. Benedict, Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines, Cancer research 37 (1977) 1364‐1371
[72] A. Valent, J. Benard, B. Clausse, M. Barrois, D. Valteau‐Couanet, M.J. Terrier‐Lacombe, B.
Spengler, A. Bernheim, In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei, The American journal of pathology 158 (2001) 1579‐1584
Supplementary information see appendix of the thesis.